Psyched Wellness Sells Out First Run of Calmer and Ramps Up Production

Psyched Wellness ( (TSE:PSYC) ) has shared an announcement.

Psyched Wellness has sold out the initial production run of its new double-strength relaxation product, Calmer, which is formulated with the company’s proprietary AME-1 extract and positioned as an enhanced version of its existing Calm offering. Driven by strong early demand and positive consumer feedback, the company has already begun a new production run and is refining the product with a double filtration process to improve flavor, underscoring growing market traction for its mushroom-derived wellness portfolio and its efforts to scale distribution and reinforce shareholder value.

The most recent analyst rating on (TSE:PSYC) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Psyched Wellness stock, see the TSE:PSYC Stock Forecast page.

Spark’s Take on TSE:PSYC Stock

According to Spark, TipRanks’ AI Analyst, TSE:PSYC is a Neutral.

The score is held down primarily by heavy losses and ongoing cash burn despite strong revenue growth, with weak technical momentum adding pressure. A debt-free balance sheet and a positive product-related corporate update provide partial offsets, but valuation support is limited due to negative earnings and no dividend.

To see Spark’s full report on TSE:PSYC stock, click here.

More about Psyched Wellness

Psyched Wellness Ltd. is a Canadian-based life sciences and health supplements company focused on researching, developing, and commercializing consumer packaged wellness products derived from its proprietary AME-1 extract of the Amanita Muscaria mushroom, targeting the growing market for mushroom-based relaxation and stress-management solutions.

Average Trading Volume: 108,498

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$4.33M

Learn more about PSYC stock on TipRanks’ Stock Analysis page.